Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Steminent BiotherapeuticsROCO:7729 -4.70%11 PB Ratio is 8.22 as of Jul. 15, 2026, which is 143% above its 10-year median of 3.38. GuruFocus rates ROCO:7729 with a GF Score™ of 11/100. The stock has 4 warning signs investors should review. Among 1,228 Biotechnology companies, Steminent Biotherapeutics ranks worse than 82.33% on this metric.
The historical rank and industry rank for Steminent Biotherapeutics's PB Ratio or its related term are showing as below:
ROCO:7729'
s PB Ratio Range Over the Past 10 Years
Min: 2.21 Med: 3.38 Max: 10.93
Current: 8.21
During the past 6 years, Steminent Biotherapeutics's highest PB Ratio was 10.93. The lowest was 2.21. And the median was 3.38.
ROCO:7729's PB Ratio is ranked worse than 82.33% of 1228
companies
in the Biotechnology industry
Industry Median: 2.895
vs ROCO:7729: 8.21
During the past 12 months, Steminent Biotherapeutics's average Book Value Per Share Growth Rate was 52.90% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 48.90% per year.
During the past 6 years, the highest 3-Year average Book Value Per Share Growth Rate of Steminent Biotherapeutics was 48.90% per year. The lowest was 13.10% per year. And the median was 31.00% per year.
Back to Basics: PB Ratio
Steminent Biotherapeutics (ROCO:7729) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Steminent Biotherapeutics PB Ratio Related Terms
Steminent Biotherapeutics PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:7729 vs VRTX, REGN, ALNY: PB Ratio Comparison
For the Biotechnology subindustry, Steminent Biotherapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Steminent Biotherapeutics PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Steminent Biotherapeutics's PB Ratio distribution charts can be found below:
* The bar in red indicates where Steminent Biotherapeutics's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Steminent Biotherapeutics (ROCO:7729) has a PB Ratio of 8.22 as of Jul. 15, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Steminent Biotherapeutics and its competitors. This is 143% above median its historical median of 3.38. Over the past decade, Steminent Biotherapeutics' PB Ratio has ranged from 2.21 to 10.93. According to the industry distribution chart, Steminent Biotherapeutics ranks #1011 out of 1228 companies in the Biotechnology industry, placing it in the top 82.3%.
Is Steminent Biotherapeutics' PB Ratio too high?
Steminent Biotherapeutics' current PB Ratio of 8.22 is 143% above median its 10-year median of 3.38. Over the past 10 years, this metric has ranged from a low of 2.21 to a high of 10.93. The Biotechnology industry median PB Ratio is 2.90. Steminent Biotherapeutics' value of 8.22 is 183.9% above this industry median. Based on the distribution chart, Steminent Biotherapeutics ranks #1011 out of 1228 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Steminent Biotherapeutics has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Steminent Biotherapeutics' PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Steminent Biotherapeutics ranks #1011 out of 1228 companies for PB Ratio. This places Steminent Biotherapeutics in the lower half of its industry. The industry median PB Ratio is 2.90. Steminent Biotherapeutics' value of 8.22 is 183.9% above this benchmark. Historically, Steminent Biotherapeutics' own PB Ratio has ranged from 2.21 to 10.93 over the past decade. While the company's 10-year median is 3.38 vs. the industry median of 2.90, Steminent Biotherapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.90, based on 1,228 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Steminent Biotherapeutics's current PB Ratio of 8.22 is 183.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Steminent Biotherapeutics and its competitors. For the Biotechnology industry, the median PB Ratio is 2.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Steminent Biotherapeutics's current PB Ratio is 8.22, which is 143% above median its own 10-year median of 3.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Steminent Biotherapeutics stock overvalued right now?
Steminent Biotherapeutics (ROCO:7729) has a current PB Ratio of 8.22. The current PB Ratio is 8.22, which is 143% above median its 10-year median of 3.38 and 183.9% above the Biotechnology industry median of 2.90. Steminent Biotherapeutics' overall GF Score™ is 11/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Steminent Biotherapeutics (ROCO:7729), the current PB Ratio is 8.22 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Steminent Biotherapeutics Inc is a international stem cell biopharmaceutical company which has stable and efficient stem cell platform technology, aiming to develop live cell drugs to treat degenerative diseases as well as acute and life-threatening diseases. With its Stemchymal which is proprietary technology platform generating the standardized, clinical grade, allogeneic stem cells isolated from human adipose tissue. It is operated in strict compliance to regulations of Taiwan, the US, and Japan.
11GF Score
Get the complete analysis for ROCO:7729
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:7729 has been successfully added to your 
